Prevention and treatment of COVID-19 by mono- and poly-clonal antibodies

Blood Transfus. 2023 Sep;21(5):375-377. doi: 10.2450/BloodTransfus.436. Epub 2023 Feb 24.

Authors

David McIntosh¹, Thierry Burnouf^{1

2

3}, Michael Karbiener⁴, Maria R Farcet⁴, Thomas R Kreil^{1

4}

Affiliations

¹ UK Plasma Action, Petersfield, United Kingdom.
² Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.
³ International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.
⁴ Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria.

No abstract available

MeSH terms

Antibodies, Monoclonal* / therapeutic use
COVID-19* / prevention & control
COVID-19* / therapy
Humans

Substances

Antibodies, Monoclonal